- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00154661
Evaluation of Clinical Efficacy of Pentoxifylline on Patients With Glomerulonephritis
September 8, 2005 updated by: National Taiwan University Hospital
we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Pentoxifylline (PTX) is a phosphodiesterase inhibitor that is widely used for the treatment of peripheral vascular occlusive disorders.
In addition, PTX has shown its ability to attenuate nephrotic syndrome secondary to membranous glomerulonephritis and lupus nephritis, and to reduce subnephrotic proteinuria due to early and advanced diabetic nephropathy.
However, data with respect to its effect on non-nephrotic primary glomerular diseases are lacking.
Moreover, while the anti-proteinuric effect of PTX has been largely attributed to down-regulation of TNF-a, it remains unknown whether other mediators, especially MCP-1, are also affected by PTX.
Because our previous works have shown that PTX attenuates proteinuria and suppresses renal MCP-1 mRNA expression in experimental glomerulonephritis in rats, we hypothesize that PTX might be effective in lowering proteinuria by modulating renal MCP-1 production in human glomerulonephritis.
This study was thereby conducted to investigate the potential anti-proteinuric and anti-MCP-1 effects of PTX in subnephrotic patients with primary glomerular diseases.
Study Type
Interventional
Enrollment
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 100
- Yung-Ming Chen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- glomerular diseases with subnephrotic proteinuria
Exclusion Criteria:
- DM, hepatitis, systemic immunologic renal diseases
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
proteinuria
|
Secondary Outcome Measures
Outcome Measure |
---|
inflammatory mediators
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Pan-Chyr Yang, Professor and vice-Dean
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2000
Study Completion
June 1, 2001
Study Registration Dates
First Submitted
September 8, 2005
First Submitted That Met QC Criteria
September 8, 2005
First Posted (Estimate)
September 12, 2005
Study Record Updates
Last Update Posted (Estimate)
September 12, 2005
Last Update Submitted That Met QC Criteria
September 8, 2005
Last Verified
June 1, 2001
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Nephritis
- Glomerulonephritis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Pentoxifylline
Other Study ID Numbers
- 152S2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Glomerulonephritis
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Shanghai University of Traditional Chinese MedicineFudan University; RenJi Hospital; Ruijin Hospital; Xinhua Hospital, Shanghai Jiao... and other collaboratorsUnknown
-
LLiuCompletedPrimary IgA NephropathyChina
-
Peking Union Medical College HospitalUnknownPrimary IgA NephropathyChina
-
Celldex TherapeuticsTerminatedC3 Glomerulonephritis | Dense Deposit Disease | Membranoproliferative Glomerulonephritis Type IIUnited States
-
Everest Medicines (China) Co.,Ltd.RecruitingPrimary Membranous NephropathyChina
-
Calliditas Therapeutics ABCompletedPrimary IgA NephropathyBelgium, United Kingdom, Denmark, Finland, Sweden, Germany, Spain, Italy, Czech Republic, Netherlands
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedC3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Mediated Membranoproliferative Glomerulonephritis | Membranoproliferative Glomerulonephritis Types I, II, and IIINetherlands, Australia, Belgium
-
Mario Negri Institute for Pharmacological ResearchAlexion PharmaceuticalsCompletedIC-MPGN | C3 Glomerulopathy | C3 Glomerulonephritis | Dense Deposit Disease | Immune Complex Membranoproliferative GlomerulonephritisItaly
-
Beijing Mabworks Biotech Co., Ltd.Recruiting
Clinical Trials on pentoxifylline
-
Hospital Universitario de CanariasUnknown
-
Beijing Tiantan HospitalCSPC Ouyi Pharmaceutical Co., Ltd.Not yet recruitingCerebral Small Vessel DiseasesChina
-
Institute of Liver and Biliary Sciences, IndiaUnknown
-
Hospital Universitario de CanariasInstituto Médico Tinerfeño IMETISAUnknown
-
Assistance Publique - Hôpitaux de ParisMerck Sharp & Dohme LLCCompletedBenign Prostatic Hyperplasia (BPH) Requiring Surgical ResectionFrance
-
University of MichiganCompletedAcute Kidney FailureUnited States
-
Alexandria UniversityNot yet recruiting
-
National Cancer Institute (NCI)CompletedFibrosis | Radiation InjuriesUnited States
-
University of Alabama at BirminghamTerminated